Toshiki Mizuno

Prof. Dr. Toshiki Mizuno

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
TTTakahiko Tokuda
Takahiko Tokuda
SSSultan A. Salem
Sultan A. Salem
DADavid Allsop
David Allsop
TMToshiki Mizuno
Toshiki Mizuno
MNMasanori Nakagawa
Masanori Nakagawa
OEOmar El-Agnaf
Omar El-Agnaf

24 August 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DTDaiki Takewaki
Daiki Takewaki
WSWataru Suda
Wataru Suda
WSWakiro Sato
Wakiro Sato
LTLena Takayasu
Lena Takayasu
NKNaveen Kumar
Naveen Kumar
TYTakashi Yamamura
Takashi Yamamura
Significance: We have compared gut microbiomes in the different stages of multiple sclerosis (MS) based on both microbial and functional analyses using fecal samples. Together with microbial composition data, metagenomic functional and metabolite data revealed a reduced level of microbial butyrate and propionate biosynthesis in the gut of relapsing remitting MS (RRMS). On the other hand, in the gut of secondary progressive MS (SPMS), we revealed an enhancement in microbial DNA mismatch repair, which was consistent with excessive fecal oxidation shown in sulfur metabolomic analysis. As elevated oxidative stress is closely associated with chronic neuroinflammation and neurodegeneration, the present result opens a way to microbiome data-assisted management of MS, useful for prevention of disease progression.

1 June 2006 in Dementia and Geriatric Cognitive Disorders
Verified
Journal Article
Closed access
YNYuriko Nakata-Kudo
Yuriko Nakata-Kudo
TMToshiki Mizuno
Toshiki Mizuno
KYKei Yamada
Kei Yamada
KSKensuke Shiga
Kensuke Shiga
KYKenji Yoshikawa
Kenji Yoshikawa
MNMasanori Nakagawa
Masanori Nakagawa
Cerebral amyloid angiopathy (CAA) is one of the cardinal pathological features in the vascular components of Alzheimer’s disease (AD). CAA itself results in disrupted microvasculature, mainly in the cerebral cortex, eventually leading to a brain cortical or subcortical hemorrhage in a population of elderly people, but clinically overt brain hemorrhages are not so frequent in AD patients. Here we assessed 50 AD patients and 26 controls to detect latent brain hemorrhages with gradient-echo T2*-weighted images, a sensitive magnetic resonance imaging technique to detect hemosiderin components in the brain. Microbleeds, demarcated as low-intensity spots in T2*-weighted images, were detected in 16.7% of AD patients without cerebrovascular disease (CVD) and in 12.5% of those with CVD, while no microbleeding was detected in the control subjects. No significant difference was observed between the microbleed-positive group and the microbleed-negative counterpart in their clinical background, such as hypertension, the use of antiplatelet drugs and smoking. In addition, white matter high intensities in the T2-weighted image were significantly more confluent in the microbleed-positive AD group than its negative counterpart. In conclusion, our evaluation of AD brains revealed that latent microbleeds in AD patients are more frequent than in normal controls. Microbleeds not being related to common hemorrhagic risk factors, but being significantly related to white matter pathologies suggested that microbleeds in AD may be associated with CAA, but not with hypertension or CVD.

1 April 2008 in Neuroradiology
Verified
Journal Article
Closed access
PDF file
KMKoushun Matsuo
Koushun Matsuo
TMToshiki Mizuno
Toshiki Mizuno
KYKei Yamada
Kei Yamada
KAKentaro Akazawa
Kentaro Akazawa
TKTakashi Kasai
Takashi Kasai
MNMasanori Nakagawa
Masanori Nakagawa

18 September 2017 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
TKT. Konno
T. Konno
KYK. Yoshida
K. Yoshida
IMIkuko Mizuta
Ikuko Mizuta
TMToshiki Mizuno
Toshiki Mizuno
TKT. Kawarai
T. Kawarai
TITakeshi Ikeuchi
Takeshi Ikeuchi

1 April 2000 in European Neurology
Verified
Journal Article
Closed access
PDF file
RFRyuichi Fukuyama
Ryuichi Fukuyama
TMToshiki Mizuno
Toshiki Mizuno
TMTetsuya Mizuno
Tetsuya Mizuno
SMSatoru Mori
Satoru Mori
KNKenji Nakajima
Kenji Nakajima
KYKatsuhiko Yanagisawa
Katsuhiko Yanagisawa
In order to address an age-dependent alteration in the concentration of β-amyloid polypeptides (Aβs) within the central nervous system and its probable predisposition to amyloidgenesis in Alzheimer’s disease (AD), we measured two species of soluble Aβs, Aβ40 and Aβ42, in cerebrospinal fluids (CSF) from randomly selected Japanese control subjects at various ages (n = 33) and then compared these data with those of probable Japanese AD patients (n = 23). CSF concentrations of Aβ40 and Aβ42 peptides were age-dependent (ANOVA, Bonferroni’s multiple comparison; p < 0.01 and p < 0.05, respectively) and were lower in the infant than in adults. From mid-20, the Aβ40 concentrations were decreasing while Aβ42 were rather stable. Aβs in CSF from AD patients (n = 23), whose ε4 allele frequency of the apolipoprotein E gene was higher than in controls (n = 83, p < 0.03), were not statistically different from those of age-matched controls (n = 13). A linear relationship was detected between the Aβ40 concentration and the Mini-Mental State Examination score (p < 0.05). The ratio of the Aβ42 to the Aβ40 level measured in the AD CSF samples was approximately 38% decreased compared to age-matched controls (p < 0.05). These data suggest that the physiological metabolism of soluble Aβs in the brain is regulated in an age-dependent manner, and that the ratio of Aβ42 to Aβ40 level in the CSF would be a useful marker for monitoring progression of AD.